Article
An online poll of New England Journal of Medicine readers shows a lack of consensus over prostate cancer screening, with a little over half of respondents recommending screening for a 55-year-old man.
Case study: 69-year-old Black man with mHSPC
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
Experts share insights on next-generation NMIBC therapies
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer